AVITA Medical Secures $25.5M BARDA Contract for Emergency Burn Treatment Preparedness
核心洞察
AVITA Medical has secured a 10-year agreement with BARDA (搜索) worth up to $25.5 million to strengthen U.S. national preparedness for burn mass casualty incidents (搜索).
The contract ensures rapid nationwide access to 3,000 units of RECELL (搜索), an FDA-approved spray-on skin technology, for emergency deployment during mass casualty events.
AVITA will maintain ready inventory and provide logistics support, with $3.97 million in guaranteed revenue over 10 years plus additional procurement options.
AVITA Medical has entered into a significant 10-year agreement with the Biomedical Advanced Research and Development Authority (BARDA (搜索)) valued at up to $25.5 million to bolster U.S. emergency preparedness for burn mass casualty incidents (搜索). The contract, awarded under Project BioShield, ensures rapid nationwide access to the company's RECELL (搜索) technology during critical emergency situations.
Strategic Emergency Response Partnership
The agreement positions AVITA Medical as a key partner in national emergency preparedness, providing BARDA (搜索) with access to 3,000 units of RECELL (搜索) products at any time throughout the 10-year contract period. "Through this agreement, AVITA is supporting national preparedness by helping expand access to RECELL during mass casualty incidents," said Cary Vance, Interim Chief Executive Officer of AVITA Medical.
Under the contract terms, AVITA Medical will maintain an inventory of RECELL (搜索) products available for immediate deployment upon notice from BARDA (搜索) and support surge procurement of additional products to ensure scalable emergency response capacity. The company will also provide comprehensive logistics, quality assurance, and deployment readiness services to meet BARDA's preparedness mission.
Financial Structure and Revenue Impact
The agreement carries a total potential value of up to $25.5 million over the 10-year period, including procurement options. Of this amount, approximately $3.97 million represents expected revenue to AVITA Medical in the form of annual access-maintenance fees and readiness support payments distributed over the contract duration. The remaining balance reflects procurement options that BARDA (搜索) may exercise throughout the contract term.
RECELL Technology and Clinical Applications
RECELL (搜索) is an FDA-approved technology for treating thermal burns (搜索) and trauma wounds (搜索) that harnesses the healing properties of a patient's own skin to create Spray-On Skin. The technology is designed to optimize wound healing and accelerate patient recovery time. In emergency scenarios, RECELL products will be deployed to designated centers with trained staff to ensure rapid and effective treatment.
The partnership underscores AVITA Medical's commitment to delivering value to the U.S. government through discounted pricing, proven manufacturing and logistics capabilities, and robust compliance standards. This latest agreement builds on a decade-long partnership between AVITA Medical and BARDA (搜索) focused on advancing burn care innovation and strengthening public health readiness.
Broader Product Portfolio
Beyond RECELL (搜索), AVITA Medical holds exclusive U.S. rights to market and distribute Cohealyx (搜索), a collagen-based dermal matrix, and manufactures PermeaDerm (搜索), a biosynthetic wound matrix. Internationally, RECELL has received regulatory approvals including CE mark in Europe, TGA registration in Australia, and PMDA approval in Japan for promoting skin healing in thermal burns (搜索) and trauma wounds (搜索).